, /PRNewswire/ -- Insmed Incorporated (Nasdaq: ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, will host a commercial webinar on , at to discuss the market outlook for the Company's three most advanced programs, ARIKAYCE (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP). Shareholders and other interested parties may participate in the conference call by dialing (800) 715-9871 (U.S.
) and (646) 307-1963 (international) and referencing access code 7504027. The call will also be webcast live on the Company's website at . A replay of the conference call will be accessible approximately 1 hour after its completion through , by dialing (800) 770-2030 (U.
S.) and (609) 800-9909 (international) and referencing access code 7504027. A webcast of the call will also be archived for 90 days under the Investor Relations section of the Company's website at .
ARIKAYCE is approved in the United States as ARIKAYCE (amikacin liposome inhalation suspension), in as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion, and in as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). Current international treatment guidelines recommend the use of ARIKAYCE for appropriate patients. ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic that was historically administered intravenously and associated with severe toxicity to hearing,.
